Review of Atorvastatin As A Potent Drug For Cardio-Vascular Disease(CVD)

Year : 2025 | Volume : 12 | 03 | Page :
    By

    Usama Kasam Rinde,

  • Sonali Dheeraj Parab,

  • Aarya Abhijit Tanawade,

  • Nikhil Mangesh Patil,

  1. Research Scholar, Department of Pharmacy, SSPM’S V P College of Pharmacy Madkhol-Sawantwadi, Maharashtra, India
  2. Assistant Professor, Department of Pharmacy, SSPM’S V P College of Pharmacy Madkhol-Sawantwadi, Maharashtra, India
  3. Assistant Professor, Department of Pharmacy, SSPM’S V P College of Pharmacy Madkhol-Sawantwadi, Maharashtra, India
  4. Assistant Professor, Department of Pharmacy, SVS’s Dadasaheb Rawal Pharmacy College, Mandal- Dondaicha, Maharashtra, India

Abstract

Cardiovascular disease (CVD), particularly atherosclerosis, remains the leading cause of death worldwide, significantly burdening public health, especially in Western societies. Metabolic syndrome and arrhythmic complications further exacerbate cardiovascular morbidity and mortality. Among restorative specialists, statins particularly atorvastatin have gotten to central in both the essential and auxiliary anticipation of coronary heart infection (CHD) due to their strong lipid-lowering properties and additional pleiotropic impacts. Atorvastatin, a selective HMG-CoA reductase inhibitor, not only reduces low-density lipoprotein cholesterol (LDL-C) by up to 60% but also improves endothelial function, decreases oxidative stress, and stabilizes atherosclerotic plaques. Long half-life and liver selectivity, advantageous pharmacokinetic profiles promote its effectiveness. Clinical studies such as Ascot-LLa, TNT, and CARDs have reduced the benefits of reducing important unwanted cardiovascular events, particularly in high-risk patients, including older adults. Despite some instances of statin intolerance, atorvastatin maintains a strong safety and efficacy record. With its broad cardiovascular benefits, cost-effectiveness, and growing role in personalized medicine, atorvastatin remains a cornerstone of modern cardiovascular risk management.

Keywords: Atherosclerotic plaque stabilization, cardiovascular disease (CVD), Pleiotropic effects, Acute coronary syndrome (ACS), Atorvastatin-HMG-CoA reductase inhibitors, Low-density lipoprotein (LDL-C) & High-density lipoprotein (HDL-C), Clinical trials (ASCOT-LLA, TNT, CARDS).

How to cite this article:
Usama Kasam Rinde, Sonali Dheeraj Parab, Aarya Abhijit Tanawade, Nikhil Mangesh Patil. Review of Atorvastatin As A Potent Drug For Cardio-Vascular Disease(CVD). Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(03):-.
How to cite this URL:
Usama Kasam Rinde, Sonali Dheeraj Parab, Aarya Abhijit Tanawade, Nikhil Mangesh Patil. Review of Atorvastatin As A Potent Drug For Cardio-Vascular Disease(CVD). Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(03):-. Available from: https://journals.stmjournals.com/rrjoddd/article=2025/view=224797


References

[1] Kjekshus J. Arrhythmias and mortality in congestive heart failure. The American journal of cardiology. 1990 May 22;65(19):42-8.
[2] B. Liptak, V. Knezl, and Z. Gasparova, “Anti-arrhythmic and cardio-protective effects of atorvastatin and a potent pyridoindole derivative on isolated hearts from rats with metabolic syndrome,” Bratislava Medical Journal, vol. 120, no. 3, pp. 200–206, 2019, doi: 10.4149/BLL_2019_034.
[3] D. Roy et al., “Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India,” PLoS One, vol. 15, no. 5, May 2020, doi: 10.1371/journal.pone.0233230.
[4] I. Elmadbouh, M. Mansour, M. Nabeh, W. Faried, A. Abdelsabour, and A. Omar, “Atorvastatin improves cardiac function and remodeling in chronic non-ischemic heart failure: A clinical and pre-clinical study,” Egyptian Heart Journal, vol. 67, no. 4, pp. 289–298, Dec. 2015, doi: 10.1016/j.ehj.2014.11.003.
[5] S. Acharjee and F. K. Welty, “Atorvastatin and cardiovascular risk in the elderly – Patient considerations,” 2008. doi: 10.2147/cia.s2442.
[6] J. C. Godoy et al., “Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes,” FASEB Journal, vol. 33, no. 1, pp. 1209–1225, Jan. 2019, doi: 10.1096/fj.201800876R.
[7] J. K. Liao, “Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol,” American Journal of Cardiology, vol. 96, no. 5 SUPPL., pp. 24–33, Sep. 2005, doi: 10.1016/j.amjcard.2005.06.009.
[8] C. Sai, J. Li, M. Ruiyan, and X. Yingbin, “Atorvastatin prevents postoperative atrial fibrillation in patients undergoing cardiac surgery,” Hellenic Journal of Cardiology, vol. 60, no. 1, pp. 40–47, Jan. 2019, doi: 10.1016/j.hjc.2017.12.012.
[9] Virani PA, Sojitra RA, Raj HA, Jain VI. A review on Irbesartan co administered with Atorvastatin for the treatment of cardiac risk. J Crit Rev. 2014;1(1):25-8.
[10] E. Raschi, M. Casula, A. F. G. Cicero, A. Corsini, C. Borghi, and A. Catapano, “Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events,” Oct. 01, 2023, Elsevier Inc. doi: 10.1016/j.pharmthera.2023.108507.
[11] K. K. Koh, I. Sakuma, K. Shimada, T. Hayashi, and M. J. Quon, “Combining potent statin therapy with other drugs to optimize simultaneous cardiovascular and metabolic benefits while minimizing adverse events,” Jul. 01, 2017, Korean Society of Cardiology. doi: 10.4070/kcj.2016.0406.
[12] U. Laufs, B. Karmann, and D. Pittrow, “Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk,” Clinical Research in Cardiology, vol. 105, no. 9, pp. 783–790, Sep. 2016, doi: 10.1007/s00392-016-0991-z.
[13] N. K. Kapur and K. Musunuru, “Clinical efficacy and safety of statins in managing cardiovascular risk,” 2008. doi: 10.2147/vhrm.s1653.
[14] Q. Zhou and J. K. Liao, “Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy.”
[15] N. Sawada and J. K. Liao, “Rho/rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis,” Mar. 10, 2014. doi: 10.1089/ars.2013.5524.
[16] M. Banach and D. P. Mikhailidis, “Statin Intolerance: Some Practical Hints,” May 01, 2018, W.B. Saunders. doi: 10.1016/j.ccl.2017.12.004.
[17] B. A. Parker et al., “Effect of statins on skeletal muscle function,” Circulation, vol. 127, no. 1, pp. 96–103, Jan. 2013, doi: 10.1161/CIRCULATIONAHA.112.136101.
[18] K. Bouillon et al., “Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study,” J Am Heart Assoc, vol. 11, no. 12, Jun. 2022, doi: 10.1161/JAHA.121.023357.
[19] F. T. Billings et al., “High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: A randomized clinical trial,” JAMA – Journal of the American Medical Association, vol. 315, no. 9, pp. 877–888, Mar. 2016, doi: 10.1001/jama.2016.0548.
[20] K. A. Bybee, J. H. Lee, and J. H. O’Keefe, “Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: The clinical impact of atorvastatin,” Apr. 2008. doi: 10.1185/030079908X292001.
[21] W. Koenig, “High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy,” Oct. 15, 2013. doi: 10.1016/j.ijcard.2013.07.113.
[22] M. Tonelli et al., “Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis,” CMAJ. Canadian Medical Association Journal, vol. 183, no. 16, Nov. 2011, doi: 10.1503/cmaj.101280.
[23] W. A. Murphy et al., “Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial,” Circ Genom Precis Med, vol. 15, no. 3, p. E003503, Jun. 2022, doi: 10.1161/CIRCGEN.121.003503.
[24] V. Singh and P. Deedwania, “Vascular Health and Risk Management Reducing morbidity and mortality in high risk patients with statins,” 2009. [Online]. Available: www.dovepress.com
[25] J. Greenwood and J. C. Mason, “Statins and the vascular endothelial inflammatory response,” Feb. 2007. doi: 10.1016/j.it.2006.12.003.
[26] P. S. Sever et al., “Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA),” 2005. [Online]. Available: www.ascotstudy.
[27] L. H. Opie and A. J. Dalby, “Cardiovascular prevention: Lifestyle and statins – Competitors or companions?,” 2014, South African Medical Association. doi: 10.7196/SAMJ.7942.
[28] F. Taylor et al., “Statins for the primary prevention of cardiovascular disease,” Jan. 31, 2013, John Wiley and Sons Ltd. doi: 10.1002/14651858.CD004816.pub5.
[29] S. Yamamuro, T. Shinozaki, S. Iimuro, and Y. Matsuyama, “Mediational g-formula for time-varying treatment and repeated-measured multiple mediators: Application to atorvastatin’s effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics,” Stat Methods Med Res, vol. 30, no. 8, pp. 1782–1799, Aug. 2021, doi: 10.1177/09622802211025988.
[30] J. Davignon, “Beneficial cardiovascular pleiotropic effects of statins,” Jun. 15, 2004, Lippincott Williams and Wilkins. doi: 10.1161/01.cir.0000131517.20177.5a.
[31] A. Oesterle, U. Laufs, and J. K. Liao, “Pleiotropic Effects of Statins on the Cardiovascular System,” Jan. 06, 2017, Lippincott Williams and Wilkins. doi: 10.1161/CIRCRESAHA.116.308537.
[32] “SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study ,” New England Journal of Medicine, vol. 359, no. 8, pp. 789–799, Aug. 2008, doi: 10.1056/nejmoa0801936.
[33] A. Loch, J. P. Bewersdorf, D. Kofink, D. Ismail, I. Z. Abidin, and R. S. Veriah, “Generic atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: A cross-sectional retrospective cohort study,” BMC Res Notes, vol. 10, no. 1, Jul. 2017, doi: 10.1186/s13104-017-2617-6.

Ahead of Print Subscription Review Article
Volume 12
03
Received 01/08/2025
Accepted 07/08/2025
Published 24/08/2025
Publication Time 23 Days
116

Login


My IP

PlumX Metrics